SG11201909229SA - Crystalline forms of (s)-afoxolaner - Google Patents
Crystalline forms of (s)-afoxolanerInfo
- Publication number
- SG11201909229SA SG11201909229SA SG11201909229SA SG11201909229SA SG 11201909229S A SG11201909229S A SG 11201909229SA SG 11201909229S A SG11201909229S A SG 11201909229SA SG 11201909229S A SG11201909229S A SG 11201909229SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- crystalline forms
- pct
- duluth
- chemin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Secondary Cells (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482175P | 2017-04-05 | 2017-04-05 | |
| PCT/US2018/026328 WO2018187623A1 (en) | 2017-04-05 | 2018-04-05 | Crystalline forms of (s)-afoxolaner |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909229SA true SG11201909229SA (en) | 2019-11-28 |
Family
ID=62092252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909229S SG11201909229SA (en) | 2017-04-05 | 2018-04-05 | Crystalline forms of (s)-afoxolaner |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10662163B2 (de) |
| EP (1) | EP3606911A1 (de) |
| JP (1) | JP7222909B2 (de) |
| KR (1) | KR102612648B1 (de) |
| CN (1) | CN111032634A (de) |
| AR (1) | AR111412A1 (de) |
| AU (1) | AU2018250304B2 (de) |
| BR (1) | BR112019021072A2 (de) |
| CA (1) | CA3059114A1 (de) |
| CL (1) | CL2019002840A1 (de) |
| CO (1) | CO2019011980A2 (de) |
| EA (1) | EA201992360A1 (de) |
| IL (1) | IL269792B (de) |
| MD (1) | MD20190080A2 (de) |
| MX (1) | MX2019011931A (de) |
| MY (1) | MY188420A (de) |
| PH (1) | PH12019502277A1 (de) |
| SG (1) | SG11201909229SA (de) |
| TW (1) | TWI782976B (de) |
| UA (1) | UA125727C2 (de) |
| UY (1) | UY37665A (de) |
| WO (1) | WO2018187623A1 (de) |
| ZA (1) | ZA201906464B (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118536571A (zh) * | 2024-05-31 | 2024-08-23 | 北京无问芯穹科技有限公司 | 一种构建扩散变换器模型的方法、系统、设备及存储介质 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201909229SA (en) * | 2017-04-05 | 2019-11-28 | Boehringer Ingelheim Animal Health Usa Inc | Crystalline forms of (s)-afoxolaner |
| WO2021254445A1 (zh) * | 2020-06-19 | 2021-12-23 | 东莞市东阳光仿制药研发有限公司 | 一种gaba抑制剂的晶型及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
| TWI430995B (zh) | 2007-06-26 | 2014-03-21 | Du Pont | 萘異唑啉無脊椎有害動物控制劑 |
| TWI649303B (zh) * | 2007-08-17 | 2019-02-01 | 杜邦股份有限公司 | 製備４-乙醯基-ｎ-〔２-側氧基-２-〔（２，２，２-三氟乙基）胺基〕乙基〕-１-萘甲醯胺之化合物及方法 |
| MA34247B1 (fr) | 2010-05-27 | 2013-05-02 | Du Pont | Forme cristalline du 4-[5-[3-chloro-5-(trifluorométhyl) phényl] -4,5-dihydro-5-(trifluorométhyl)-3-isoxazolyl]-n-[2-oxo-2-[(2, 2,2-trifluoroéthyl) amino] éthyl]-1-naphtalènecarboxamide |
| DK3172964T3 (da) * | 2011-09-12 | 2020-11-30 | Boehringer Ingelheim Animal Health Usa Inc | Parasitiske sammensætninger indeholdende et isoxazolinaktivstof, fremgangsmåde og anvendelser deraf |
| WO2014090918A1 (en) * | 2012-12-13 | 2014-06-19 | Novartis Ag | Process for the enantiomeric enrichment of diaryloxazoline derivatives |
| JP2015028006A (ja) * | 2013-06-27 | 2015-02-12 | 日産化学工業株式会社 | イソキサゾリン化合物の結晶性多形体およびその製造方法 |
| UY36570A (es) * | 2015-02-26 | 2016-10-31 | Merial Inc | Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas |
| KR102593069B1 (ko) * | 2015-04-08 | 2023-10-23 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 이속사졸린 활성제를 포함하는 서방형 주사 제형, 이의 방법 및 용도 |
| MX2020013754A (es) | 2016-04-06 | 2022-07-25 | Boehringer Ingelheim Animal Health Usa Inc | Proceso para preparar compuestos de isoxazolina. |
| SG11201909229SA (en) * | 2017-04-05 | 2019-11-28 | Boehringer Ingelheim Animal Health Usa Inc | Crystalline forms of (s)-afoxolaner |
-
2018
- 2018-04-05 SG SG11201909229S patent/SG11201909229SA/en unknown
- 2018-04-05 EP EP18721541.3A patent/EP3606911A1/de active Pending
- 2018-04-05 EA EA201992360A patent/EA201992360A1/ru unknown
- 2018-04-05 KR KR1020197032461A patent/KR102612648B1/ko active IP Right Grant
- 2018-04-05 MX MX2019011931A patent/MX2019011931A/es unknown
- 2018-04-05 JP JP2019554802A patent/JP7222909B2/ja active Active
- 2018-04-05 US US15/946,642 patent/US10662163B2/en active Active
- 2018-04-05 AR ARP180100859A patent/AR111412A1/es unknown
- 2018-04-05 CN CN201880033276.6A patent/CN111032634A/zh active Pending
- 2018-04-05 MD MDA20190080A patent/MD20190080A2/ro unknown
- 2018-04-05 MY MYPI2019005850A patent/MY188420A/en unknown
- 2018-04-05 CA CA3059114A patent/CA3059114A1/en active Pending
- 2018-04-05 BR BR112019021072-5A patent/BR112019021072A2/pt active Search and Examination
- 2018-04-05 WO PCT/US2018/026328 patent/WO2018187623A1/en active Application Filing
- 2018-04-05 AU AU2018250304A patent/AU2018250304B2/en active Active
- 2018-04-05 UY UY0001037665A patent/UY37665A/es unknown
- 2018-04-05 UA UAA201910863A patent/UA125727C2/uk unknown
- 2018-04-09 TW TW107112164A patent/TWI782976B/zh active
-
2019
- 2019-10-01 ZA ZA2019/06464A patent/ZA201906464B/en unknown
- 2019-10-02 PH PH12019502277A patent/PH12019502277A1/en unknown
- 2019-10-03 IL IL269792A patent/IL269792B/en unknown
- 2019-10-04 CL CL2019002840A patent/CL2019002840A1/es unknown
- 2019-10-28 CO CONC2019/0011980A patent/CO2019011980A2/es unknown
-
2020
- 2020-03-20 US US16/825,616 patent/US11130739B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118536571A (zh) * | 2024-05-31 | 2024-08-23 | 北京无问芯穹科技有限公司 | 一种构建扩散变换器模型的方法、系统、设备及存储介质 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7222909B2 (ja) | 2023-02-15 |
| AU2018250304B2 (en) | 2022-03-03 |
| EA201992360A1 (ru) | 2020-09-02 |
| KR20190136055A (ko) | 2019-12-09 |
| US11130739B2 (en) | 2021-09-28 |
| KR102612648B1 (ko) | 2023-12-11 |
| IL269792A (en) | 2019-11-28 |
| CL2019002840A1 (es) | 2020-01-10 |
| WO2018187623A8 (en) | 2019-10-24 |
| UA125727C2 (uk) | 2022-05-25 |
| PH12019502277A1 (en) | 2020-09-14 |
| US20180354917A1 (en) | 2018-12-13 |
| MD20190080A2 (ro) | 2020-04-30 |
| EP3606911A1 (de) | 2020-02-12 |
| US20200270219A1 (en) | 2020-08-27 |
| AU2018250304A1 (en) | 2019-10-31 |
| CN111032634A (zh) | 2020-04-17 |
| MY188420A (en) | 2021-12-08 |
| ZA201906464B (en) | 2021-08-25 |
| TWI782976B (zh) | 2022-11-11 |
| IL269792B (en) | 2022-04-01 |
| TW201841895A (zh) | 2018-12-01 |
| UY37665A (es) | 2018-10-31 |
| AR111412A1 (es) | 2019-07-10 |
| US10662163B2 (en) | 2020-05-26 |
| BR112019021072A2 (pt) | 2020-05-12 |
| JP2020513010A (ja) | 2020-04-30 |
| MX2019011931A (es) | 2020-01-13 |
| CO2019011980A2 (es) | 2020-02-18 |
| WO2018187623A1 (en) | 2018-10-11 |
| CA3059114A1 (en) | 2018-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201900947RA (en) | Tlr7/8 antagonists and uses thereof | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201811706RA (en) | Process for the preparation of microcapsules | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201906464UA (en) | Csf1r-based chimeric proteins | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |